{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T18:34:16Z","timestamp":1793385256935,"version":"4.5.0"},"reference-count":136,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T00:00:00Z","timestamp":1779321600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Recurrent or metastatic head and neck squamous cell carcinoma (R\/M HNSCC) is a highly aggressive disease entity with poor prognosis. Current systemic treatment regimens, including chemotherapy, targeted therapy, and immune checkpoint inhibitors, provide only limited and often short-lived clinical benefits. As an innovative therapeutic approach, antibody-drug conjugates (ADCs) combine the tumor-targeting specificity of monoclonal antibodies with the potent cytotoxicity of the conjugated payload, enabling selective delivery of highly active drugs to cancer cells. Given the urgent need to improve clinical outcomes for R\/M HNSCC, ADCs have emerged as a highly promising therapeutic strategy and are increasingly becoming the focus of translational research and clinical trials, with encouraging signals observed in both early and late-stage trials. This review comprehensively outlines the biological principles, antigen targets, and current clinical development progress of ADCs in treating R\/M HNSCC. It begins with a brief explanation of ADC structural principles, followed by a systematic summary of all preclinical and clinical evidence supporting ADC therapy.<\/jats:p>","DOI":"10.3389\/fimmu.2026.1828131","type":"journal-article","created":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T05:43:30Z","timestamp":1779342210000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":2,"title":["Antibody-drug conjugates in recurrent or metastatic HNSCC: relevant targets, clinical development, and future prospects"],"prefix":"10.3389","volume":"17","author":[{"given":"Hu","family":"Zhao","sequence":"first","affiliation":[{"name":"Otorhinolaryngology and Head and Neck Surgery, The First Hospital of Shanxi Medical University","place":["Taiyuan, China"]},{"name":"First Clinical Medical College, Shanxi Medical University","place":["Taiyuan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Senxuan","family":"Zhang","sequence":"additional","affiliation":[{"name":"First Clinical Medical College, Shanxi Medical University","place":["Taiyuan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fang","family":"Wang","sequence":"additional","affiliation":[{"name":"First Clinical Medical College, Shanxi Medical University","place":["Taiyuan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peirong","family":"Yu","sequence":"additional","affiliation":[{"name":"First Clinical Medical College, Shanxi Medical University","place":["Taiyuan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin","family":"Li","sequence":"additional","affiliation":[{"name":"First Clinical Medical College, Shanxi Medical University","place":["Taiyuan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lina","family":"Jia","sequence":"additional","affiliation":[{"name":"Otorhinolaryngology and Head and Neck Surgery, The First Hospital of Shanxi Medical University","place":["Taiyuan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pengfei","family":"He","sequence":"additional","affiliation":[{"name":"Otorhinolaryngology and Head and Neck Surgery, The First Hospital of Shanxi Medical University","place":["Taiyuan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Run","family":"Liu","sequence":"additional","affiliation":[{"name":"Otorhinolaryngology and Head and Neck Surgery, The First Hospital of Shanxi Medical University","place":["Taiyuan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian","family":"Zhang","sequence":"additional","affiliation":[{"name":"Otorhinolaryngology and Head and Neck Surgery, The First Hospital of Shanxi Medical University","place":["Taiyuan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"KeXin","family":"Wang","sequence":"additional","affiliation":[{"name":"Otorhinolaryngology and Head and Neck Surgery, The First Hospital of Shanxi Medical University","place":["Taiyuan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rui","family":"Han","sequence":"additional","affiliation":[{"name":"Otorhinolaryngology and Head and Neck Surgery, The First Hospital of Shanxi Medical University","place":["Taiyuan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Huangfu","sequence":"additional","affiliation":[{"name":"Otorhinolaryngology and Head and Neck Surgery, The First Hospital of Shanxi Medical University","place":["Taiyuan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,5,21]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21834","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J Clin"},{"key":"B2","doi-asserted-by":"publisher","first-page":"994","DOI":"10.1634\/theoncologist.2009-0289","article-title":"Changes in survival in head and neck cancers in the late 20th and early 21st century: a period analysis","volume":"15","author":"Pulte","year":"2010","journal-title":"Oncologist"},{"key":"B3","doi-asserted-by":"publisher","first-page":"10","DOI":"10.3322\/caac.70028","article-title":"Cancer statistics, 2025","volume":"75","author":"Siegel","year":"2025","journal-title":"CA Cancer J Clin"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.mct-24-0281","article-title":"Advanced human papillomavirus-negative head and neck squamous cell carcinoma: Unmet need and emerging therapies","volume":"23","author":"Park","year":"2024","journal-title":"Mol Cancer Ther"},{"key":"B5","doi-asserted-by":"publisher","first-page":"3936155261428136","DOI":"10.1177\/03936155261428136","article-title":"HPV-positive head and neck squamous cell carcinoma: From molecular pathogenesis to therapeutic frontiers","author":"Li","year":"2026","journal-title":"Int J Biol Markers"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2025.3136","article-title":"Emerging EGFR-targeted therapy in head and neck cancer: A review","volume":"11","author":"Hwang","year":"2025","journal-title":"JAMA Oncol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2025.105904","article-title":"Whole-exome ctDNA sequencing reveals intratumoral heterogeneity and drivers of relapse in locally advanced head and neck cancer","volume":"10","author":"Bruixola","year":"2025","journal-title":"ESMO Open"},{"key":"B8","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1038\/s41392-026-02645-0","article-title":"Anti-PD-1 antibody penpulimab plus chemotherapy for recurrent or metastatic nasopharyngeal carcinoma: a randomized, double-blind phase 3 study","volume":"11","author":"Huang","year":"2026","journal-title":"Signal Transduct Target Ther"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa053422","article-title":"Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck","volume":"354","author":"Bonner","year":"2006","journal-title":"N Engl J Med"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/s1470-2045(17)30421-7","article-title":"Nivolumab versus standard, single-agent therapy of investigator's choice in recurrent or metastatic squamous cell carcinoma of the head and neck (CheckMate 141): health-related quality-of-life results from a randomised, phase 3 trial","volume":"18","author":"Harrington","year":"2017","journal-title":"Lancet Oncol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1016\/s1470-2045(16)30066-3","article-title":"Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012): an open-label, multicentre, phase 1b trial","volume":"17","author":"Seiwert","year":"2016","journal-title":"Lancet Oncol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(25)02053-7","article-title":"The arrival of antibody drug conjugates in nasopharyngeal cancer","volume":"406","author":"Chan","year":"2025","journal-title":"Lancet"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1038\/s41577-025-01207-9","article-title":"Fifty years of monoclonals: the past, present and future of antibody therapeutics","volume":"25","author":"Chan","year":"2025","journal-title":"Nat Rev Immunol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1016\/j.medj.2025.100849","article-title":"Antibody-drug conjugates: Current challenges and innovative solutions for precision cancer therapy","volume":"6","author":"Zhou","year":"2025","journal-title":"Med"},{"key":"B15","doi-asserted-by":"publisher","first-page":"115161","DOI":"10.1016\/j.colsurfb.2025.115161","article-title":"Antibody-drug conjugates (ADCs): \"Smart Missiles\" targeting cancer therapy","volume":"257","author":"Yao","year":"2025","journal-title":"Colloids Surf B Biointerfaces"},{"key":"B16","doi-asserted-by":"publisher","first-page":"1164","DOI":"10.3390\/pharmaceutics17091164","article-title":"Strategic and chemical advances in antibody-drug conjugates","volume":"17","author":"Alradwan","year":"2025","journal-title":"Pharmaceutics"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.ccr-14-0012","article-title":"FDA approval: ado-trastuzumab emtansine for the treatment of patients with HER2-positive metastatic breast cancer","volume":"20","author":"Amiri-Kordestani","year":"2014","journal-title":"Clin Cancer Res"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1200\/jco-25-00812","article-title":"US Food and Drug Administration approval summary: trastuzumab deruxtecan for the treatment of adult patients with hormone receptor-positive, unresectable or metastatic human epidermal growth factor receptor 2-low or human epidermal growth factor receptor 2-ultralow breast cancer","volume":"43","author":"Dilawari","year":"2025","journal-title":"J Clin Oncol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.ccr-20-4557","article-title":"FDA approval summary: fam-trastuzumab deruxtecan-nxki for the treatment of unresectable or metastatic HER2-positive breast cancer","volume":"27","author":"Narayan","year":"2021","journal-title":"Clin Cancer Res"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.ccr-20-3119","article-title":"FDA approval summary: accelerated approval of sacituzumab govitecan-hziy for third-line treatment of metastatic triple-negative breast cancer","volume":"27","author":"Wahby","year":"2021","journal-title":"Clin Cancer Res"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1038\/s43018-025-01042-w","article-title":"Past, present and future of drug conjugates for cancer therapy","volume":"6","author":"Cazzamalli","year":"2025","journal-title":"Nat Cancer"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1016\/j.addr.2025.115648","article-title":"Antibody-drug conjugates as multimodal therapies against hard-to-treat cancers","volume":"224","author":"Armstrong","year":"2025","journal-title":"Adv Drug Delivery Rev"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1016\/j.jncc.2025.01.007","article-title":"Advancements in antibody-drug conjugates as cancer therapeutics","volume":"5","author":"Fong","year":"2025","journal-title":"J Natl Cancer Cent"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2020.107753","article-title":"Tumor microenvironment as a therapeutic target in cancer","volume":"221","author":"Xiao","year":"2021","journal-title":"Pharmacol Ther"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1093\/procel\/pwaf002","article-title":"The Icarian flight of antibody-drug conjugates: target selection amidst complexity and tackling adverse impacts","volume":"16","author":"Liu","year":"2025","journal-title":"Protein Cell"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.ccr-25-0839","article-title":"Antibody-drug conjugates in non-small cell lung cancer: Where are the target and the biomarker","volume":"31","author":"Hirsch","year":"2025","journal-title":"Clin Cancer Res"},{"key":"B27","doi-asserted-by":"publisher","first-page":"217685","DOI":"10.1016\/j.canlet.2025.217685","article-title":"A high-affinity antibody-drug conjugates Actuximab-MMAE for potent and selective targeting of CEACAM5-positive tumors","volume":"620","author":"Hu","year":"2025","journal-title":"Cancer Lett"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1516419","article-title":"Antibody-drug conjugates in cancer therapy: applications and future advances","volume":"16","author":"Long","year":"2025","journal-title":"Front Immunol"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-020-00876-4","article-title":"How to select IgG subclasses in developing anti-tumor therapeutic antibodies","volume":"13","author":"Yu","year":"2020","journal-title":"J Hematol Oncol"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1038\/s41573-023-00709-2","article-title":"Antibody-drug conjugates come of age in oncology","volume":"22","author":"Dumontet","year":"2023","journal-title":"Nat Rev Drug Discov"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1038\/nrd.2018.46","article-title":"The expanding role of prodrugs in contemporary drug design and development","volume":"17","author":"Rautio","year":"2018","journal-title":"Nat Rev Drug Discov"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-023-00850-2","article-title":"Exploring the next generation of antibody-drug conjugates","volume":"21","author":"Tsuchikama","year":"2024","journal-title":"Nat Rev Clin Oncol"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1016\/j.tips.2025.04.002","article-title":"Molecular glue meets antibody: next-generation antibody-drug conjugates","volume":"46","author":"Tao","year":"2025","journal-title":"Trends Pharmacol Sci"},{"key":"B34","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1038\/s43018-020-00136-x","article-title":"Immune-stimulating antibody conjugates elicit robust myeloid activation and durable antitumor immunity","volume":"2","author":"Ackerman","year":"2021","journal-title":"Nat Cancer"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.2c01791","article-title":"Degrader-antibody conjugates: emerging new modality","volume":"66","author":"Hong","year":"2023","journal-title":"J Med Chem"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.can-21-3236","article-title":"Pathophysiologic and pharmacologic considerations to improve the design and application of antibody-drug conjugates","volume":"82","author":"Boghaert","year":"2022","journal-title":"Cancer Res"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1080\/19420862.2025.2498162","article-title":"Homogeneous antibody-drug conjugates with dual payloads: potential, methods and considerations","volume":"17","author":"Wen","year":"2025","journal-title":"MAbs"},{"key":"B38","doi-asserted-by":"publisher","first-page":"967","DOI":"10.3390\/pharmaceutics17080967","article-title":"A dual-payload bispecific ADC improved potency and efficacy over single-payload bispecific ADCs","volume":"17","author":"Wilski","year":"2025","journal-title":"Pharmaceutics"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2024.116995","article-title":"Dual-payload antibody-drug conjugates: Taking a dual shot","volume":"281","author":"Tao","year":"2025","journal-title":"Eur J Med Chem"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2021.687926","article-title":"Linker design impacts antibody-drug conjugate pharmacokinetics and efficacy via modulating the stability and payload release efficiency","volume":"12","author":"Su","year":"2021","journal-title":"Front Pharmacol"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.2017.367","article-title":"Antibody drug conjugates and bystander killing: is antigen-dependent internalisation required","volume":"117","author":"Staudacher","year":"2017","journal-title":"Br J Cancer"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1080\/2162402x.2025.2533488","article-title":"Immunogenic cell death and bystander killing: expanding the therapeutic potential of modern antibody-drug conjugates","volume":"14","author":"Kepp","year":"2025","journal-title":"Oncoimmunology"},{"key":"B43","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1186\/s12967-025-06589-x","article-title":"Research advancements of antibody drug conjugates in non-small cell lung cancer with HER2 alterations","volume":"23","author":"Liu","year":"2025","journal-title":"J Transl Med"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.can-15-1795","article-title":"Intracellular released payload influences potency and bystander-killing effects of antibody-drug conjugates in preclinical models","volume":"76","author":"Li","year":"2016","journal-title":"Cancer Res"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.5c01982","article-title":"Recent advances in peptide linkers for antibody-drug conjugates","author":"Li","year":"2025","journal-title":"J Med Chem"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1002\/psc.70040","article-title":"Peptide-drug conjugates: a new hope for cancer","volume":"31","author":"Armstrong","year":"2025","journal-title":"J Pept Sci"},{"key":"B47","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1186\/s12951-025-03277-2","article-title":"Current progress and remaining challenges of peptide-drug conjugates (PDCs): next generation of antibody-drug conjugates (ADCs)","volume":"23","author":"Wang","year":"2025","journal-title":"J Nanobiotechnology"},{"key":"B48","doi-asserted-by":"publisher","first-page":"104355","DOI":"10.1016\/j.critrevonc.2024.104355","article-title":"Trastuzumab deruxtecan in breast cancer","volume":"198","author":"Mart\u00edn","year":"2024","journal-title":"Crit Rev Oncol Hematol"},{"key":"B49","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1002\/cac2.12517","article-title":"Development of antibody-drug conjugates in cancer: overview and prospects","volume":"44","author":"Ruan","year":"2024","journal-title":"Cancer Commun (Lond)"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2025.117863","article-title":"Evolution of TROP2: biological insights and clinical applications","volume":"296","author":"Zhang","year":"2025","journal-title":"Eur J Med Chem"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1038\/nature14129","article-title":"Comprehensive genomic characterization of head and neck squamous cell carcinomas","volume":"517","author":"Stransky","year":"2015","journal-title":"Nature"},{"key":"B52","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1038\/d41573-025-00027-9","article-title":"Fda approves TROP2-targeted antibody-drug conjugate for breast cancer","volume":"24","author":"Mullard","year":"2025","journal-title":"Nat Rev Drug Discov"},{"key":"B53","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1146\/annurev-med-071322-065903","article-title":"Leveraging TROP2 antibody-drug conjugates in solid tumors","volume":"75","author":"Nelson","year":"2024","journal-title":"Annu Rev Med"},{"key":"B54","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1016\/j.lungcan.2021.12.002","article-title":"Antibody-drug conjugates: a promising novel therapeutic approach in lung cancer","volume":"163","author":"Desai","year":"2022","journal-title":"Lung Cancer"},{"key":"B55","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1186\/s13045-021-01035-z","article-title":"Antibody-drug conjugates in solid tumors: a look into novel targets","volume":"14","author":"Criscitiello","year":"2021","journal-title":"J Hematol Oncol"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2021.03.005","article-title":"Sacituzumab govitecan, a Trop-2-directed antibody-drug conjugate, for patients with epithelial cancer: final safety and efficacy results from the phase I\/II IMMU-132\u201301 basket trial","volume":"32","author":"Bardia","year":"2021","journal-title":"Ann Oncol"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa1814213","article-title":"Sacituzumab govitecan-hziy in refractory metastatic triple-negative breast cancer","volume":"380","author":"Bardia","year":"2019","journal-title":"N Engl J Med"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-024-03269-z","article-title":"Sacituzumab govitecan in HR(+)HER2(-) metastatic breast cancer: the randomized phase 3 EVER-132\u2013002 trial","volume":"30","author":"Xu","year":"2024","journal-title":"Nat Med"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.ccr-23-3924","article-title":"Sacituzumab govitecan demonstrates efficacy across tumor Trop-2 expression levels in patients with advanced urothelial cancer","volume":"30","author":"Loriot","year":"2024","journal-title":"Clin Cancer Res"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.ccr-24-2523","article-title":"Sacituzumab govitecan in patients with relapsed\/refractory advanced head and neck squamous cell carcinoma: results from the phase II TROPiCS-03 basket study","volume":"31","author":"Michel","year":"2025","journal-title":"Clin Cancer Res"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2025.103023","article-title":"Datopotamab deruxtecan: rational strategies, novel advancements, challenges, and future perspectives","volume":"140","author":"Di Lauro","year":"2025","journal-title":"Cancer Treat Rev"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.mct-21-0206","article-title":"Datopotamab deruxtecan, a novel TROP2-directed antibody-drug conjugate, demonstrates potent antitumor activity by efficient drug delivery to tumor cells","volume":"20","author":"Okajima","year":"2021","journal-title":"Mol Cancer Ther"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1016\/s1357-2725(99)00015-1","article-title":"Egf receptor","volume":"31","author":"Wells","year":"1999","journal-title":"Int J Biochem Cell Biol"},{"key":"B64","doi-asserted-by":"publisher","first-page":"1618","DOI":"10.3390\/cancers11101618","article-title":"A comprehensive review on MAPK: a promising therapeutic target in cancer","volume":"11","author":"Braicu","year":"2019","journal-title":"Cancers (Basel)"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1038\/35052073","article-title":"Untangling the ErbB signalling network","volume":"2","author":"Yarden","year":"2001","journal-title":"Nat Rev Mol Cell Biol"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.3389\/fmolb.2022.847835","article-title":"Antibody-drug conjugates targeting the human epidermal growth factor receptor family in cancers","volume":"9","author":"Yu","year":"2022","journal-title":"Front Mol Biosci"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2022.0503","article-title":"Evaluation of safety of treatment with anti-epidermal growth factor receptor antibody drug conjugate MRG003 in patients with advanced solid tumors: a phase 1 nonrandomized clinical trial","volume":"8","author":"Qiu","year":"2022","journal-title":"JAMA Oncol"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.mct-15-0901","article-title":"Abt-414, an antibody-drug conjugate targeting a tumor-selective EGFR epitope","volume":"15","author":"Phillips","year":"2016","journal-title":"Mol Cancer Ther"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.1093\/carcin\/bgae014","article-title":"Efficacy of depatuxizumab mafodotin (ABT-414) in preclinical models of head and neck cancer","volume":"45","author":"Mani","year":"2024","journal-title":"Carcinogenesis"},{"key":"B70","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1158\/1535-7163.mct-17-0710","article-title":"Characterization of ABBV-221, a tumor-selective EGFR-targeting antibody drug conjugate","volume":"17","author":"Phillips","year":"2018","journal-title":"Mol Cancer Ther"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.1007\/s10637-020-00908-3","article-title":"A phase 1 study evaluating safety and pharmacokinetics of losatuxizumab vedotin (ABBV-221), an anti-EGFR antibody-drug conjugate carrying monomethyl auristatin E, in patients with solid tumors likely to overexpress EGFR","volume":"38","author":"Cleary","year":"2020","journal-title":"Invest New Drugs"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.1126\/science.2999974","article-title":"Tyrosine kinase receptor with extensive homology to EGF receptor shares chromosomal location with neu oncogene","volume":"230","author":"Coussens","year":"1985","journal-title":"Science"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.7554\/elife.00708","article-title":"Her2 activation mechanism reflects evolutionary preservation of asymmetric ectodomain dimers in the human EGFR family","volume":"2","author":"Arkhipov","year":"2013","journal-title":"Elife"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.1093\/emboj\/17.12.3385","article-title":"Differential endocytic routing of homo- and hetero-dimeric ErbB tyrosine kinases confers signaling superiority to receptor heterodimers","volume":"17","author":"Lenferink","year":"1998","journal-title":"EMBO J"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.1002\/hed.10307","article-title":"Prognostic significance of tumor angiogenesis, Ki 67, p53 oncoprotein, epidermal growth factor receptor and HER2 receptor protein expression in undifferentiated nasopharyngeal carcinoma--a prospective study","volume":"25","author":"Ma","year":"2003","journal-title":"Head Neck"},{"key":"B76","doi-asserted-by":"publisher","first-page":"4774","DOI":"10.3390\/ijms22094774","article-title":"Trastuzumab deruxtecan: changing the destiny of HER2 expressing solid tumors","volume":"22","author":"Indini","year":"2021","journal-title":"Int J Mol Sci"},{"key":"B77","doi-asserted-by":"publisher","first-page":"688","DOI":"10.1158\/2159-8290.cd-19-1014","article-title":"Targeting HER2 with trastuzumab deruxtecan: a dose-expansion, phase I study in multiple advanced solid tumors","volume":"10","author":"Tsurutani","year":"2020","journal-title":"Cancer Discov"},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-020-01281-4","article-title":"Trastuzumab deruxtecan: first approval","volume":"80","author":"Keam","year":"2020","journal-title":"Drugs"},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.1002\/1878-0261.70056","article-title":"Molecular imaging predicts trastuzumab-deruxtecan (T-DXd) response in head and neck cancer xenograft models","volume":"19","author":"Naveed","year":"2025","journal-title":"Mol Oncol"},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.1002\/j.1460-2075.1994.tb06577.x","article-title":"Identification of c-erbB-3 binding sites for phosphatidylinositol 3'-kinase and SHC using an EGF receptor\/c-erbB-3 chimera","volume":"13","author":"Prigent","year":"1994","journal-title":"EMBO J"},{"key":"B81","doi-asserted-by":"publisher","DOI":"10.1097\/ppo.0000000000000622","article-title":"Her2 and HER3 as therapeutic targets in head and neck cancer","volume":"28","author":"Saddawi-Konefka","year":"2022","journal-title":"Cancer J"},{"key":"B82","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.mct-19-0163","article-title":"Neuregulin signaling is a mechanism of therapeutic resistance in head and neck squamous cell carcinoma","volume":"18","author":"Baro","year":"2019","journal-title":"Mol Cancer Ther"},{"key":"B83","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1158\/2159-8290.CD-21-0715","article-title":"Efficacy and safety of patritumab deruxtecan (HER3-DXd) in EGFR inhibitor-resistant, EGFR-mutated non-small cell lung cancer","volume":"12","author":"J\u00e4nne","year":"2022","journal-title":"Cancer Discov"},{"key":"B84","doi-asserted-by":"publisher","DOI":"10.1007\/s40262-025-01521-4","article-title":"Integrated two-analyte population pharmacokinetics model of patritumab deruxtecan (HER3-DXd) monotherapy in patients with solid tumors","volume":"64","author":"Xu","year":"2025","journal-title":"Clin Pharmacokinet"},{"key":"B85","doi-asserted-by":"publisher","DOI":"10.1200\/jco.23.01476","article-title":"HERTHENA-Lung01, a phase II trial of patritumab deruxtecan (HER3-DXd) in epidermal growth factor receptor-mutated non-small-cell lung cancer after epidermal growth factor receptor tyrosine kinase inhibitor therapy and platinum-based chemotherapy","volume":"41","author":"Yu","year":"2023","journal-title":"J Clin Oncol"},{"key":"B86","doi-asserted-by":"publisher","DOI":"10.1200\/jco.23.00882","article-title":"Patritumab deruxtecan (HER3-DXd), a human epidermal growth factor receptor 3-directed antibody-drug conjugate, in patients with previously treated human epidermal growth factor receptor 3-expressing metastatic breast cancer: a multicenter, phase I\/II trial","volume":"41","author":"Krop","year":"2023","journal-title":"J Clin Oncol"},{"key":"B87","doi-asserted-by":"publisher","DOI":"10.1080\/14796694.2025.2561539","article-title":"HERTHENA-PanTumor01: a phase II study of patritumab deruxtecan (HER3-DXd) in previously treated advanced solid tumors","volume":"21","author":"Powles","year":"2025","journal-title":"Future Oncol"},{"key":"B88","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2021.174516","article-title":"Nectin cell adhesion molecule-4 (NECTIN-4): a potential target for cancer therapy","volume":"911","author":"Chatterjee","year":"2021","journal-title":"Eur J Pharmacol"},{"key":"B89","doi-asserted-by":"publisher","DOI":"10.7554\/elife.00358","article-title":"A role for PVRL4-driven cell-cell interactions in tumorigenesis","volume":"2","author":"Pavlova","year":"2013","journal-title":"Elife"},{"key":"B90","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.28299","article-title":"Nectin-4 is widely expressed in head and neck squamous cell carcinoma","volume":"13","author":"Sanders","year":"2022","journal-title":"Oncotarget"},{"key":"B91","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2022.40.6_suppl.568","article-title":"Clinical pharmacology of the antibody-drug conjugate enfortumab vedotin in advanced urothelial carcinoma and other Malignant solid tumors","volume":"63","author":"Tang","year":"2024","journal-title":"Clin Pharmacokinet"},{"key":"B92","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa2035807","article-title":"Enfortumab vedotin in previously treated advanced urothelial carcinoma","volume":"384","author":"Powles","year":"2021","journal-title":"N Engl J Med"},{"key":"B93","doi-asserted-by":"publisher","DOI":"10.1200\/jco.19.02044","article-title":"EV-101: a phase I study of single-agent enfortumab vedotin in patients with nectin-4-positive solid tumors, including metastatic urothelial carcinoma","volume":"38","author":"Rosenberg","year":"2020","journal-title":"J Clin Oncol"},{"key":"B94","doi-asserted-by":"publisher","DOI":"10.1200\/jco.24.00646","article-title":"Phase II trial of enfortumab vedotin in patients with previously treated advanced head and neck cancer","volume":"43","author":"Swiecicki","year":"2025","journal-title":"J Clin Oncol"},{"key":"B95","doi-asserted-by":"publisher","DOI":"10.1007\/s10555-023-10137-8","article-title":"B7-H3 at the crossroads between tumor plasticity and colorectal cancer progression: a potential target for therapeutic intervention","volume":"43","author":"Varghese","year":"2024","journal-title":"Cancer Metastasis Rev"},{"key":"B96","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2023.114890","article-title":"B7-H3 immunoregulatory roles in cancer","volume":"163","author":"Mortezaee","year":"2023","journal-title":"BioMed Pharmacother"},{"key":"B97","doi-asserted-by":"publisher","first-page":"e007174","DOI":"10.1136\/jitc-2023-007174","article-title":"Antitumor activity of the investigational B7-H3 antibody-drug conjugate, vobramitamab duocarmazine, in preclinical models of neuroblastoma","volume":"11","author":"Brignole","year":"2023","journal-title":"J Immunother Cancer"},{"key":"B98","doi-asserted-by":"publisher","DOI":"10.1158\/1538-7445.am2018-820","article-title":"Preclinical development of MGC018, a duocarmycin-based antibody-drug conjugate targeting B7-H3 for solid cancer","volume":"19","author":"Scribner","year":"2020","journal-title":"Mol Cancer Ther"},{"key":"B99","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-025-03600-2","article-title":"A B7H3-targeting antibody-drug conjugate in advanced solid tumors: a phase 1\/1b trial","volume":"31","author":"Ma","year":"2025","journal-title":"Nat Med"},{"key":"B100","doi-asserted-by":"publisher","DOI":"10.1002\/pro.5560070718","article-title":"Identification of a frizzled-like cysteine rich domain in the extracellular region of developmental receptor tyrosine kinases","volume":"7","author":"Saldanha","year":"1998","journal-title":"Protein Sci"},{"key":"B101","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1016\/j.tripleo.2008.08.018","article-title":"Ror2 expression in squamous cell carcinoma and epithelial dysplasia of the oral cavity","volume":"107","author":"Kobayashi","year":"2009","journal-title":"Oral Surg Oral Med Oral Pathol Oral Radiol Endod"},{"key":"B102","doi-asserted-by":"publisher","DOI":"10.1080\/19420862.2025.2490078","article-title":"Preclinical development of ozuriftamab vedotin (BA3021), a novel ROR2-specific conditionally active biologic antibody-drug conjugate","volume":"17","author":"Chang","year":"2025","journal-title":"MAbs"},{"key":"B103","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2024.08.929","article-title":"868P Phase II trial of ozuriftamab vedotin (BA3021), a conditionally active biologic (CAB)-ROR2-ADC, in patients with recurrent or metastatic squamous cell carcinoma of the head and neck (R\/M SCCHN)","volume":"35","author":"Wong","year":"2024","journal-title":"Ann Oncol"},{"key":"B104","doi-asserted-by":"publisher","DOI":"10.1055\/s-0039-1687894","article-title":"Tissue factor and cancer: regulation, tumor growth, and metastasis","volume":"45","author":"Hisada","year":"2019","journal-title":"Semin Thromb Hemost"},{"key":"B105","doi-asserted-by":"publisher","DOI":"10.1002\/cnr2.1699","article-title":"Systematic study of tissue factor expression in solid tumors","volume":"6","author":"de Bono","year":"2023","journal-title":"Cancer Rep (Hoboken)"},{"key":"B106","doi-asserted-by":"publisher","DOI":"10.1177\/17588359241277647","article-title":"Antibody drug conjugates in recurrent or metastatic cervical cancer: a focus on tisotumab vedotin state of art","volume":"16","author":"Camarda","year":"2024","journal-title":"Ther Adv Med Oncol"},{"key":"B107","doi-asserted-by":"publisher","DOI":"10.2147\/cmar.s294080","article-title":"Therapeutic potential of tisotumab vedotin in the treatment of recurrent or metastatic cervical cancer: a short report on the emerging data","volume":"15","author":"Agostinelli","year":"2023","journal-title":"Cancer Manag Res"},{"key":"B108","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-021-01633-8","article-title":"Tisotumab vedotin: first approval","volume":"81","author":"Markham","year":"2021","journal-title":"Drugs"},{"key":"B109","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2021.12.028","article-title":"Efficacy and safety of tisotumab vedotin in patients with head and neck squamous cell carcinoma: results from a phase II cohort","volume":"112","author":"Hong","year":"2022","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"B110","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-24-0002","article-title":"Preclinical characterization of XB002, an anti-tissue factor antibody-drug conjugate for the treatment of solid tumors","volume":"24","author":"Kantak","year":"2025","journal-title":"Mol Cancer Ther"},{"key":"B111","doi-asserted-by":"publisher","first-page":"12346","DOI":"10.3390\/ijms232012346","article-title":"Integrin alpha v beta 6 (\u03b1v\u03b26) and its implications in cancer treatment","volume":"23","author":"Brzozowska","year":"2022","journal-title":"Int J Mol Sci"},{"key":"B112","doi-asserted-by":"publisher","DOI":"10.1016\/s1368-8375(01)00062-8","article-title":"Tenascin and beta 6 integrin are overexpressed in floor of mouth in situ carcinomas and invasive squamous cell carcinomas","volume":"38","author":"Regezi","year":"2002","journal-title":"Oral Oncol"},{"key":"B113","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.mct-22-0817","article-title":"SGN-B6A: a new vedotin antibody-drug conjugate directed to integrin beta-6 for multiple carcinoma indications","volume":"22","author":"Lyon","year":"2023","journal-title":"Mol Cancer Ther"},{"key":"B114","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2023.41.16_suppl.3024","article-title":"SGN-B6A, an integrin beta-6 (ITGB6)-targeted antibody-drug conjugate (ADC), in patients with advanced solid tumors: updated results from a phase 1 study (SGNB6A-001)","volume":"41","author":"Hollebecque","year":"2023","journal-title":"J Clin Oncol"},{"key":"B115","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2018.00097","article-title":"CD44\/CD44v6 a reliable companion in cancer-initiating cell maintenance and tumor progression","volume":"6","author":"Wang","year":"2018","journal-title":"Front Cell Dev Biol"},{"key":"B116","doi-asserted-by":"publisher","DOI":"10.1016\/s0167-8140(07)80090-9","article-title":"A phase I dose escalation study with anti-CD44v6 bivatuzumab mertansine in patients with incurable squamous cell carcinoma of the head and neck or esophagus","volume":"12","author":"Tijink","year":"2006","journal-title":"Clin Cancer Res"},{"key":"B117","doi-asserted-by":"publisher","DOI":"10.1016\/j.oraloncology.2007.10.009","article-title":"Phase I trial with the CD44v6-targeting immunoconjugate bivatuzumab mertansine in head and neck squamous cell carcinoma","volume":"44","author":"Riechelmann","year":"2008","journal-title":"Oral Oncol"},{"key":"B118","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.ccr-07-1054","article-title":"Overexpression of cellular iron import proteins is associated with Malignant progression of esophageal adenocarcinoma","volume":"14","author":"Boult","year":"2008","journal-title":"Clin Cancer Res"},{"key":"B119","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0051120","article-title":"The activation pattern of blood leukocytes in head and neck squamous cell carcinoma is correlated to survival","volume":"7","author":"Millrud","year":"2012","journal-title":"PloS One"},{"key":"B120","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.mct-21-0193","article-title":"Nonclinical efficacy and safety of CX-2029, an anti-CD71 probody-drug conjugate","volume":"21","author":"Singh","year":"2022","journal-title":"Mol Cancer Ther"},{"key":"B121","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.ccr-21-0194","article-title":"Phase I, first-in-human study of the probody therapeutic CX-2029 in adults with advanced solid tumor Malignancies","volume":"27","author":"Johnson","year":"2021","journal-title":"Clin Cancer Res"},{"key":"B122","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1007\/s10585-019-09957-2","article-title":"Modulation of cell adhesion and migration through regulation of the immunoglobulin superfamily member ALCAM\/CD166","volume":"36","author":"von Lersner","year":"2019","journal-title":"Clin Exp Metastasis"},{"key":"B123","doi-asserted-by":"publisher","DOI":"10.1016\/j.prp.2014.06.012","article-title":"Activated leukocyte cell adhesion molecule (ALCAM\/CD166) expression in head and neck squamous cell carcinoma (HNSSC)","volume":"210","author":"Clauditz","year":"2014","journal-title":"Pathol Res Pract"},{"key":"B124","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.ccr-21-3656","article-title":"Praluzatamab ravtansine, a CD166-targeting antibody-drug conjugate, in patients with advanced solid tumors: an open-label phase I\/II trial","volume":"28","author":"Boni","year":"2022","journal-title":"Clin Cancer Res"},{"key":"B125","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.ccr-18-2951","article-title":"The CD98 heavy chain is a marker and regulator of head and neck squamous cell carcinoma radiosensitivity","volume":"25","author":"Digomann","year":"2019","journal-title":"Clin Cancer Res"},{"key":"B126","doi-asserted-by":"publisher","DOI":"10.1016\/j.tranon.2024.101981","article-title":"A novel SLC3A2-targeting antibody-drug conjugate exerts potent antitumor efficacy in head and neck squamous cell cancer","volume":"45","author":"Zheng","year":"2024","journal-title":"Transl Oncol"},{"key":"B127","doi-asserted-by":"publisher","DOI":"10.1055\/s-0032-1332048","article-title":"Downregulation of P-cadherin expression in hepatocellular carcinoma induces tumorigenicity","volume":"7","author":"Bauer","year":"2014","journal-title":"Int J Clin Exp Pathol"},{"key":"B128","doi-asserted-by":"publisher","DOI":"10.20944\/preprints202310.1888.v1","article-title":"Dual blockage of P-cadherin and c-Met synergistically inhibits the growth of head and neck cancer","volume":"48","author":"Liu","year":"2025","journal-title":"Cell Oncol (Dordr)"},{"key":"B129","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.mct-20-0708","article-title":"PCA062, a P-cadherin targeting antibody-drug conjugate, displays potent antitumor activity against P-cadherin-expressing Malignancies","volume":"20","author":"Sheng","year":"2021","journal-title":"Mol Cancer Ther"},{"key":"B130","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.mct-21-0652","article-title":"A first-in-human, phase I, multicenter, open-label, dose-escalation study of PCA062: an antibody-drug conjugate targeting P-cadherin, in patients with solid tumors","volume":"21","author":"Duca","year":"2022","journal-title":"Mol Cancer Ther"},{"key":"B131","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(25)01954-3","article-title":"Izalontamab brengitecan, an EGFR and HER3 bispecific antibody-drug conjugate, versus chemotherapy in heavily pretreated recurrent or metastatic nasopharyngeal carcinoma: a multicentre, randomised, open-label, phase 3 study in China","volume":"406","author":"Yang","year":"2025","journal-title":"Lancet"},{"key":"B132","doi-asserted-by":"publisher","DOI":"10.1200\/jco-25-02200","article-title":"Antibody-drug conjugates and bispecific antibodies for lymphoma: partners of convenience or a perfect match","volume":"43","author":"Dickinson","year":"2025","journal-title":"J Clin Oncol"},{"key":"B133","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.ccr-25-0206","article-title":"Izalontamab (SI-B001), a novel EGFRxHER3 bispecific antibody in patients with locally advanced or metastatic epithelial tumor: results from first-in-human phase I\/Ib study","volume":"31","author":"Xue","year":"2025","journal-title":"Clin Cancer Res"},{"key":"B134","doi-asserted-by":"publisher","first-page":"3817","DOI":"10.3390\/cancers17233817","article-title":"Emerging and investigational systemic therapies in recurrent\/metastatic head and neck cancer after progression on immunotherapy","volume":"17","author":"Abraham","year":"2025","journal-title":"Cancers (Basel)"},{"key":"B135","doi-asserted-by":"publisher","DOI":"10.1093\/abt\/tbaf017","article-title":"Reprogramming the tumor microenvironment: synergistic mechanisms of antibody-drug conjugates and immune checkpoint inhibitors","volume":"8","author":"Yin","year":"2025","journal-title":"Antib Ther"},{"key":"B136","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1632705","article-title":"Another power of antibody-drug conjugates: immunomodulatory effect and clinical applications","volume":"16","author":"Shi","year":"2025","journal-title":"Front Immunol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1828131\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T05:43:33Z","timestamp":1779342213000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1828131\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,21]]},"references-count":136,"alternative-id":["10.3389\/fimmu.2026.1828131"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1828131","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,21]]},"article-number":"1828131"}}